Diapath LabTalks: Evaluation of HER2 status in breast cancer

HER2 Assessment in Breast CancerПодробнее

The evolution of HER2 targeting in metastatic breast breast cancerПодробнее

Dr. Tripathy on Determining the Best HER2 Targeted TherapyПодробнее

HER2DX and pCR in HER2-positive breast cancer: a combined analysis of 4 neoadjuvant studiesПодробнее

Evolving and Emerging Trends in HER2 Classification and Reporting in Breast CancerПодробнее

Guidelines and Approaches to HER2 Testing for Breast CancerПодробнее

Study of Immunotherapy Combinations for Patients with HER2-Positive Metastatic Breast CancerПодробнее

Testing for HER2 Expression in Breast Cancer PatientsПодробнее

Future of breast cancer care: HER2 therapies in earlier settings & de-escalationПодробнее

The genetics of breast cancer complete responseПодробнее

HER2CLIMB and NALA Trials: R/R HER2+ mBCПодробнее

A New View of the Spectrum of HER2 Expression and Significance of HER2 Low in Breast CancerПодробнее

Systemic Therapies Shown to be Effective in HER2-Positive Breast CancerПодробнее

Dr. Tripathy on Targeting HER2 in Breast CancerПодробнее

Dr. Hamilton Discusses Challenges With Approved Treatments for HER2-Positive Breast CancerПодробнее

Dr. Pegram on Challenges in Neoadjuvant Treatment for HER2-Positive Breast CancerПодробнее

Approaching HER2 Testing in Breast CancerПодробнее